GEP-NET
Clinical trials for GEP-NET explained in plain language.
Never miss a new study
Get alerted when new GEP-NET trials appear
Sign up with your email to follow new studies for GEP-NET, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough gut tumors: RYZ101 trial targets patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that cannot be removed by surgery and have grown after prior treatment with a type of radiation therapy (177Lu). The trial has two parts: first, finding the best dose, t…
Matched conditions: GEP-NET
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Radioactive drug RYZ401 targets Hard-to-Treat tumors in first human trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…
Matched conditions: GEP-NET
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
450 patients join study to unlock secrets of rare gut tumors
Knowledge-focused Recruiting nowThis study looks at how factors like age, sex, and tumor grade influence how well treatments work for a type of rare gut cancer called GEP-NENs. Researchers will follow 450 adults with well-differentiated tumors who are receiving standard therapies such as somatostatin analogs or…
Matched conditions: GEP-NET
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 26, 2026 03:55 UTC